Venrock Healthcare Capital Partners
Venture capitalNew York · 3 people tracked
Also known as Venrock Healthcare Capital Partners EG · Venrock Healthcare Capital Partners XP
Find your way into Venrock Healthcare Capital Partners
Fund manager profile
Venrock Healthcare Capital Partners is a venture fund manager based in New York. SEC filings show 5 venture funds on record, most recently Venrock Healthcare Capital Partners XP, L.P. ($500M offering) filed November 2024.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 3 people
from public directoriesWhat they invest in
from 11 of 11 portfolio companiesBiotech ×10Healthtech ×6AI & Machine Learning ×1Cloud Computing ×1Enterprise Software ×1Fintech ×1Medical Devices ×1SaaS ×1
HQs:United States×10
Investments · 11 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 12024 · 22023 · 12019 · 18 dated
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Henderson(Chief Executive Officer and Director)in
Co-investorsAccess BiotechnologyRA CapitalPerceptive Xontogeny VentureRTW Investments L.P.
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Janus Henderson Investors+1 more
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)Eliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalJanus Henderson InvestorsOrbiMed+2 more
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalSamsara BioCapital+2 more
Applied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need.
BiotechHealthtechNew York, US
Shoshana Shendelman(Executive Officer, Director)in
BoardLes Funtleyder(Director)
Co-investorsEvolution VC PartnersAlexandria
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Co-investors5AM VenturesAisling CapitalBain Capital Life SciencesFrazier Life SciencesRA CapitalVivo Capital+1 more
BiotechCambridge, US
Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)
BoardMartin Murphy(Director)
Co-investorsBain Capital Life SciencesCasdin CapitalLifeSci Venture Partners
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)
BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)in
Co-investorsForesite CapitalNextech InvestJanus Henderson InvestorsRA CapitalViking Global Investors
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvus+4 more
Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.
Cloud ComputingEnterprise SoftwareFintechSaaS
Co-investorsNycaNyca PartnersARCH Venture PartnersFidelity InvestmentsInvusOrbiMed+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 5
4 IPOs · 1 acquisitions · showing 4Apogee TherapeuticsNASDAQ: APGEMaze TherapeuticsNASDAQ: MAZERelmada TherapeuticsNASDAQ: RLMDUpstream BioNASDAQ: UPB
Portfolio news
latest coverage across their companies
Cidara Therapeutics · tradingkey.com · Aug 20, 2026
Kinnate Biopharma · labusinessjournal.com · Aug 17, 2026
Relmada Therapeutics · fool.com · Aug 14, 2026
Upstream Bio · stocktitan.net · Aug 11, 2026
Lycia Therapeutics · intelligence360.news · Jul 22, 2026
Maze Therapeutics · simplywall.st · Jul 17, 2026
Mirador · latimes.com · Feb 4, 2026
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Apogee Therapeutics | 14.8% | $62.00 | Mar 2024 | $108.5M |
| Upstream Bio | 3.5% | $17.00 | Oct 2024 | $30.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Venrock Healthcare Capital Partners made?
- Venrock Healthcare Capital Partners has 11 tracked investments, 5 of which have exited, including 4 dated in the last 24 months.
- Where is Venrock Healthcare Capital Partners located?
- Venrock Healthcare Capital Partners is headquartered in New York, US.